MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells

18 October 2002

journal article
research article
Published by Springer Nature in Cancer Gene Therapy

Vol. 9 (11) , 946-950
https://doi.org/10.1038/sj.cgt.7700509

Abstract

The unique antigen-presenting capabilities of dendritic cells (DCs) make them an attractive means with which to initiate an antitumor immune response. Using DCs transduced with tumor antigens for immunotherapy has several theoretical advantages over peptide-pulsed DCs including the possibility that transduced DCs are capable of presenting epitopes on both class I and class II MHC molecules. To test this theory, we inserted the human tumor antigen gp100 into mouse DCs transgenic for HLA-DRβ1*0401 using either adenoviral vector or a VSV-G pseudotyped retroviral vector. DCs transduced with tumor antigen were able to be recognized by both a murine CD8⁺ T-cell clone and a murine CD4⁺ T-cell line in a cytokine release assay, thereby demonstrating presentation of both MHC class I and class II gp100 epitopes. This study describes the simultaneous presentation of a tumor-associated antigen to both CD4⁺ and CD8⁺ T cells and lends support to the use of gene-modified DCs as a means to initiate both CD4⁺ and CD8⁺ antitumor responses.

Keywords

This publication has 23 references indexed in Scilit:

Progress in human tumour immunology and immunotherapy
Nature, 2001
Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo
The Journal of Experimental Medicine, 2000
The promise of nucleic acid vaccines
Gene Therapy, 2000
MHC Class I–Restricted CTL Responses to Exogenous Antigens
Immunity, 1996
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
The Journal of Experimental Medicine, 1996
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
The Journal of Experimental Medicine, 1996
Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
The Journal of Experimental Medicine, 1996
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.
Proceedings of the National Academy of Sciences, 1995
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Proceedings of the National Academy of Sciences, 1993
Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones.
The Journal of Experimental Medicine, 1986